Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$85.74M
EPS-0.6700
P/E Ratio-3.35
Earnings Date08/05/2026

sera

Depreciation and Amortization

Last Annual Value

940.00K

3-Year CAGR

8%

5-Year CAGR

1%

10-Year CAGR

%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Depreciation and Amortization

SERA · NASDAQ
CompanyDepreciation and Amortization
CAGR 3Y
CAGR 5Y
CAGR 10Y
940.00K
1.5%7.4%N/A 
3.25M
1.6%16.3%N/A
655.00K
-1.8%-6.2%-1.1%
16.25K
10.5%N/AN/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
15.66M
-1.6%17.2%N/A
273.00K
-44.5%2.9%17.1%
2.20M
9.4%-12.2%19.0%
635.00K
6.1%5.9%28.1%
1.53M
16.4%5.5%15.3%
872.00M
604.0%1068.7%N/A
71.27K
-26.2%-28.5%15.6%
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.245